Boston, MA 04/30/2014 (wallstreetpr) – One of the innovative multi-specialty health care companies, Allergan, Inc. (NYSE:AGN), known for innovative and meaningful treatment is struggling to save its acquisition. Owing to its condition and growth, several offers have been made towards its acquisition. Thus, the company is trying to grab every opportunity to overcome its acquisition phase.
Exploration of White Knight
Recently Allergan, Inc. (NYSE:AGN) has approached Sanofi SA (EPA:SAN) and Johnson & Johnson (NYSE:JNJ) to figure out the possibility to find out if either of the company is interested in acquiring the Allergan Inc. It has started exploring options after getting an unsolicited bid worth $45.7 billion. The bid is from Valeant Pharmaceuticals Intl Inc the Allergan Company is exploring and negotiating with both the above mentioned companies and still in a fix to accept the alternate offer posed by the Valent.
Allergan is exploring to find a white knight with Irvine with an aim to make its acquisition tougher. Another white knight identified by the company could be German Bayer AG. (NYSE:BAYN). Investment banks have approached the German Manufacturing Company to find its interest in merging with Allergan. Further, recent speculation created a buzz in the market of its alliance with Ackman to acquire Allergan.
In the light of the latest move by Valeant, Allergan, Inc. (NYSE:AGN) has recently on April 22, 2014 has recently launched the adoption of one-year-stockholder rights plan. The Board of Director declared the date of effectuation of the plan as April 22, 2014. It further declared a dividend distribution too. The dividend will be distributed of one preferred share purchase right on each outstanding share of Allergan common stock. Further details can be explored from the Form 8-K filed by the company.
Investigation of Adequacy of Prices
Charles C. Foti, Former Attorney General of Louisiana along with KSF law firm is investigating the alleged sale of Allergan Inc. to Valeant Pharmaceuticals. After Preliminary and detailed investigation the duo confirmed that the shareholders of the Allergan Company are expected to receive $48.30 in cash under the proposed transaction. Further, it also confirmed that the shareholders would additionally receive 0.83 shares of common stock of Valeant for each share of Allergan common stock. The KSF Law firm is further investigating the matter to determine whether the alleged deal undervalues the company or is adequate to proceed with the sale.
